·         Beyfortus® (nirsevimab) is the first monoclonal antibody approved to protect all infants born during or entering their 1st Respiratory Syncytial Virus (RSV) season ·         Dr. Reddy’s receives exclusive rights from Sanofi to promote and distribute Beyfortus® in India ·         This announcement follows Dr. Reddy’s successful exclusive distribution partnership with Sanofi for their